Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension

A Phase II Multicenter, Randomized, Double-blind Clinical Trial

Il Suk Sohn, Chong Jin Kim, Taehoon Ahn, Ho Joong Youn, Hui Kyung Jeon, Sang Hyun Ihm, Eun Joo Cho, Woo Baek Chung, Shung Chull Chae, Woo Shik Kim, Chang Wook Nam, Seong Mi Park, Ji Yong Choi, Young Kwon Kim, Taek Jong Hong, Hae Young Lee, Jang Hyun Cho, Eun Seok Shin, Junghan Yoon, Tae Hyun Yang & 3 others Myung Ho Jeong, Jun Hee Lee, Joong Il Park

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose Intensive blood pressure (BP) lowering is important for the treatment of hypertension; however, it has been a challenge to achieve target BP in many patients. The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by examining the tolerability and efficacy of CAN/AML combination therapy compared with those of monotherapy with either drug in patients with essential hypertension. Methods This Phase II multicenter, randomized, double-blind clinical trial enrolled patients aged 19 years or older with essential hypertension, defined as a mean sitting diastolic BP (msDBP) between 95 and 115 mm Hg, and a mean sitting systolic BP (msSBP) of <200 mm Hg after a 2-week placebo run-in period. A total of 635 patients were screened, of whom 439 were randomized to receive treatment; 425 patients were included in the full analysis set (combination therapy, 212; monotherapy, 213). Participants were randomly assigned to receive 1 of 8 treatments: CAN (8 or 16 mg), AML (5 or 10 mg), CAN/AML (8 mg/5 mg, 8 mg/10 mg, 16 mg/5 mg, or 16 mg/10 mg), once daily for 8 weeks. Findings After 8 weeks of treatment, changes in msDBP were significantly greater in the groups receiving CAN/AML combination therapies compared with monotherapies at matched doses, with the exception of CAN 8 mg/AML 10 mg versus AML 10 mg. The response to treatment and the achievement of target BP (both msSBP and msDBP) at week 8 were significantly greater overall in the groups that received combination therapy versus monotherapy. All medications were relatively well tolerated in each group. Implications Eight-week administration of CAN/AML (8 mg/5 mg, 16 mg/5 mg, and 16 mg/10 mg) resulted in a significantly greater BP reduction than that with CAN or AML monotherapy, and was determined to be well tolerated. ClinicalTrials.gov identifier: NCT02944734.

Original languageEnglish
Pages (from-to)1628-1638
Number of pages11
JournalClinical Therapeutics
Volume39
Issue number8
DOIs
Publication statusPublished - 2017 Aug 1

Fingerprint

Amlodipine
Clinical Trials
Blood Pressure
Therapeutics
Essential Hypertension
candesartan
candesartan cilexetil
Placebos
Hypertension

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Sohn, Il Suk ; Kim, Chong Jin ; Ahn, Taehoon ; Youn, Ho Joong ; Jeon, Hui Kyung ; Ihm, Sang Hyun ; Cho, Eun Joo ; Chung, Woo Baek ; Chae, Shung Chull ; Kim, Woo Shik ; Nam, Chang Wook ; Park, Seong Mi ; Choi, Ji Yong ; Kim, Young Kwon ; Hong, Taek Jong ; Lee, Hae Young ; Cho, Jang Hyun ; Shin, Eun Seok ; Yoon, Junghan ; Yang, Tae Hyun ; Jeong, Myung Ho ; Lee, Jun Hee ; Park, Joong Il. / Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension : A Phase II Multicenter, Randomized, Double-blind Clinical Trial. In: Clinical Therapeutics. 2017 ; Vol. 39, No. 8. pp. 1628-1638.
@article{3c2eb746ecba419d807fd7e01798683b,
title = "Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial",
abstract = "Purpose Intensive blood pressure (BP) lowering is important for the treatment of hypertension; however, it has been a challenge to achieve target BP in many patients. The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by examining the tolerability and efficacy of CAN/AML combination therapy compared with those of monotherapy with either drug in patients with essential hypertension. Methods This Phase II multicenter, randomized, double-blind clinical trial enrolled patients aged 19 years or older with essential hypertension, defined as a mean sitting diastolic BP (msDBP) between 95 and 115 mm Hg, and a mean sitting systolic BP (msSBP) of <200 mm Hg after a 2-week placebo run-in period. A total of 635 patients were screened, of whom 439 were randomized to receive treatment; 425 patients were included in the full analysis set (combination therapy, 212; monotherapy, 213). Participants were randomly assigned to receive 1 of 8 treatments: CAN (8 or 16 mg), AML (5 or 10 mg), CAN/AML (8 mg/5 mg, 8 mg/10 mg, 16 mg/5 mg, or 16 mg/10 mg), once daily for 8 weeks. Findings After 8 weeks of treatment, changes in msDBP were significantly greater in the groups receiving CAN/AML combination therapies compared with monotherapies at matched doses, with the exception of CAN 8 mg/AML 10 mg versus AML 10 mg. The response to treatment and the achievement of target BP (both msSBP and msDBP) at week 8 were significantly greater overall in the groups that received combination therapy versus monotherapy. All medications were relatively well tolerated in each group. Implications Eight-week administration of CAN/AML (8 mg/5 mg, 16 mg/5 mg, and 16 mg/10 mg) resulted in a significantly greater BP reduction than that with CAN or AML monotherapy, and was determined to be well tolerated. ClinicalTrials.gov identifier: NCT02944734.",
author = "Sohn, {Il Suk} and Kim, {Chong Jin} and Taehoon Ahn and Youn, {Ho Joong} and Jeon, {Hui Kyung} and Ihm, {Sang Hyun} and Cho, {Eun Joo} and Chung, {Woo Baek} and Chae, {Shung Chull} and Kim, {Woo Shik} and Nam, {Chang Wook} and Park, {Seong Mi} and Choi, {Ji Yong} and Kim, {Young Kwon} and Hong, {Taek Jong} and Lee, {Hae Young} and Cho, {Jang Hyun} and Shin, {Eun Seok} and Junghan Yoon and Yang, {Tae Hyun} and Jeong, {Myung Ho} and Lee, {Jun Hee} and Park, {Joong Il}",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.clinthera.2017.06.014",
language = "English",
volume = "39",
pages = "1628--1638",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "8",

}

Sohn, IS, Kim, CJ, Ahn, T, Youn, HJ, Jeon, HK, Ihm, SH, Cho, EJ, Chung, WB, Chae, SC, Kim, WS, Nam, CW, Park, SM, Choi, JY, Kim, YK, Hong, TJ, Lee, HY, Cho, JH, Shin, ES, Yoon, J, Yang, TH, Jeong, MH, Lee, JH & Park, JI 2017, 'Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial', Clinical Therapeutics, vol. 39, no. 8, pp. 1628-1638. https://doi.org/10.1016/j.clinthera.2017.06.014

Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension : A Phase II Multicenter, Randomized, Double-blind Clinical Trial. / Sohn, Il Suk; Kim, Chong Jin; Ahn, Taehoon; Youn, Ho Joong; Jeon, Hui Kyung; Ihm, Sang Hyun; Cho, Eun Joo; Chung, Woo Baek; Chae, Shung Chull; Kim, Woo Shik; Nam, Chang Wook; Park, Seong Mi; Choi, Ji Yong; Kim, Young Kwon; Hong, Taek Jong; Lee, Hae Young; Cho, Jang Hyun; Shin, Eun Seok; Yoon, Junghan; Yang, Tae Hyun; Jeong, Myung Ho; Lee, Jun Hee; Park, Joong Il.

In: Clinical Therapeutics, Vol. 39, No. 8, 01.08.2017, p. 1628-1638.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension

T2 - A Phase II Multicenter, Randomized, Double-blind Clinical Trial

AU - Sohn, Il Suk

AU - Kim, Chong Jin

AU - Ahn, Taehoon

AU - Youn, Ho Joong

AU - Jeon, Hui Kyung

AU - Ihm, Sang Hyun

AU - Cho, Eun Joo

AU - Chung, Woo Baek

AU - Chae, Shung Chull

AU - Kim, Woo Shik

AU - Nam, Chang Wook

AU - Park, Seong Mi

AU - Choi, Ji Yong

AU - Kim, Young Kwon

AU - Hong, Taek Jong

AU - Lee, Hae Young

AU - Cho, Jang Hyun

AU - Shin, Eun Seok

AU - Yoon, Junghan

AU - Yang, Tae Hyun

AU - Jeong, Myung Ho

AU - Lee, Jun Hee

AU - Park, Joong Il

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Purpose Intensive blood pressure (BP) lowering is important for the treatment of hypertension; however, it has been a challenge to achieve target BP in many patients. The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by examining the tolerability and efficacy of CAN/AML combination therapy compared with those of monotherapy with either drug in patients with essential hypertension. Methods This Phase II multicenter, randomized, double-blind clinical trial enrolled patients aged 19 years or older with essential hypertension, defined as a mean sitting diastolic BP (msDBP) between 95 and 115 mm Hg, and a mean sitting systolic BP (msSBP) of <200 mm Hg after a 2-week placebo run-in period. A total of 635 patients were screened, of whom 439 were randomized to receive treatment; 425 patients were included in the full analysis set (combination therapy, 212; monotherapy, 213). Participants were randomly assigned to receive 1 of 8 treatments: CAN (8 or 16 mg), AML (5 or 10 mg), CAN/AML (8 mg/5 mg, 8 mg/10 mg, 16 mg/5 mg, or 16 mg/10 mg), once daily for 8 weeks. Findings After 8 weeks of treatment, changes in msDBP were significantly greater in the groups receiving CAN/AML combination therapies compared with monotherapies at matched doses, with the exception of CAN 8 mg/AML 10 mg versus AML 10 mg. The response to treatment and the achievement of target BP (both msSBP and msDBP) at week 8 were significantly greater overall in the groups that received combination therapy versus monotherapy. All medications were relatively well tolerated in each group. Implications Eight-week administration of CAN/AML (8 mg/5 mg, 16 mg/5 mg, and 16 mg/10 mg) resulted in a significantly greater BP reduction than that with CAN or AML monotherapy, and was determined to be well tolerated. ClinicalTrials.gov identifier: NCT02944734.

AB - Purpose Intensive blood pressure (BP) lowering is important for the treatment of hypertension; however, it has been a challenge to achieve target BP in many patients. The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by examining the tolerability and efficacy of CAN/AML combination therapy compared with those of monotherapy with either drug in patients with essential hypertension. Methods This Phase II multicenter, randomized, double-blind clinical trial enrolled patients aged 19 years or older with essential hypertension, defined as a mean sitting diastolic BP (msDBP) between 95 and 115 mm Hg, and a mean sitting systolic BP (msSBP) of <200 mm Hg after a 2-week placebo run-in period. A total of 635 patients were screened, of whom 439 were randomized to receive treatment; 425 patients were included in the full analysis set (combination therapy, 212; monotherapy, 213). Participants were randomly assigned to receive 1 of 8 treatments: CAN (8 or 16 mg), AML (5 or 10 mg), CAN/AML (8 mg/5 mg, 8 mg/10 mg, 16 mg/5 mg, or 16 mg/10 mg), once daily for 8 weeks. Findings After 8 weeks of treatment, changes in msDBP were significantly greater in the groups receiving CAN/AML combination therapies compared with monotherapies at matched doses, with the exception of CAN 8 mg/AML 10 mg versus AML 10 mg. The response to treatment and the achievement of target BP (both msSBP and msDBP) at week 8 were significantly greater overall in the groups that received combination therapy versus monotherapy. All medications were relatively well tolerated in each group. Implications Eight-week administration of CAN/AML (8 mg/5 mg, 16 mg/5 mg, and 16 mg/10 mg) resulted in a significantly greater BP reduction than that with CAN or AML monotherapy, and was determined to be well tolerated. ClinicalTrials.gov identifier: NCT02944734.

UR - http://www.scopus.com/inward/record.url?scp=85024864077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024864077&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2017.06.014

DO - 10.1016/j.clinthera.2017.06.014

M3 - Article

VL - 39

SP - 1628

EP - 1638

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 8

ER -